Literature DB >> 19716794

RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells.

Ulrik Doehn1, Camilla Hauge, Scott R Frank, Claus J Jensen, Katarzyna Duda, Jakob V Nielsen, Michael S Cohen, Jens V Johansen, Benny R Winther, Leif R Lund, Ole Winther, Jack Taunton, Steen H Hansen, Morten Frödin.   

Abstract

The RAS-stimulated RAF-MEK-ERK pathway confers epithelial cells with critical motile and invasive capacities during development, tissue regeneration, and carcinoma progression, often via promoting the epithelial-mesenchymal transition (EMT). Many mechanisms by which ERK exerts this control remain elusive. We demonstrate that the ERK-activated kinase RSK is necessary to induce mesenchymal motility and invasive capacities in nontransformed epithelial and carcinoma cells. RSK is sufficient to induce certain motile responses. Expression profiling analysis revealed that a primary role of RSK is to induce transcription of a potent promotile/invasive gene program by FRA1-dependent and -independent mechanisms. The program enables RSK to coordinately modulate the extracellular environment, the intracellular motility apparatus, and receptors mediating communication between these compartments to stimulate motility and invasion. These findings uncover a mechanism whereby the RAS-ERK pathway controls epithelial cell motility by identifying RSK as a key effector, from which emanate multiple highly coordinate transcription-dependent mechanisms for stimulation of motility and invasive properties.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19716794      PMCID: PMC3784321          DOI: 10.1016/j.molcel.2009.08.002

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  41 in total

1.  Functional overlap between two classes of matrix-degrading proteases in wound healing.

Authors:  L R Lund; J Romer; T H Bugge; B S Nielsen; T L Frandsen; J L Degen; R W Stephens; K Danø
Journal:  EMBO J       Date:  1999-09-01       Impact factor: 11.598

Review 2.  AP-1: a double-edged sword in tumorigenesis.

Authors:  Robert Eferl; Erwin F Wagner
Journal:  Nat Rev Cancer       Date:  2003-11       Impact factor: 60.716

3.  ERK activation propagates in epithelial cell sheets and regulates their migration during wound healing.

Authors:  Yutaka Matsubayashi; Miki Ebisuya; Sakiko Honjoh; Eisuke Nishida
Journal:  Curr Biol       Date:  2004-04-20       Impact factor: 10.834

4.  Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.

Authors:  Jeffrey A Smith; Celeste E Poteet-Smith; Yaming Xu; Timothy M Errington; Sidney M Hecht; Deborah A Lannigan
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

Review 5.  IQGAP1: a key regulator of adhesion and migration.

Authors:  Jun Noritake; Takashi Watanabe; Kazumasa Sato; Shujie Wang; Kozo Kaibuchi
Journal:  J Cell Sci       Date:  2005-05-15       Impact factor: 5.285

6.  Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion.

Authors:  L M Shaw; I Rabinovitz; H H Wang; A Toker; A M Mercurio
Journal:  Cell       Date:  1997-12-26       Impact factor: 41.582

Review 7.  Plasminogen activation and cancer.

Authors:  Keld Danø; Niels Behrendt; Gunilla Høyer-Hansen; Morten Johnsen; Leif R Lund; Michael Ploug; John Rømer
Journal:  Thromb Haemost       Date:  2005-04       Impact factor: 5.249

8.  Constitutively active mutant of the mitogen-activated protein kinase kinase MEK1 induces epithelial dedifferentiation and growth inhibition in madin-darby canine kidney-C7 cells.

Authors:  H Schramek; E Feifel; E Healy; V Pollack
Journal:  J Biol Chem       Date:  1997-04-25       Impact factor: 5.157

9.  TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells.

Authors:  M Oft; J Peli; C Rudaz; H Schwarz; H Beug; E Reichmann
Journal:  Genes Dev       Date:  1996-10-01       Impact factor: 11.361

10.  Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids.

Authors:  Richard C Bates; Jeffrey D Goldsmith; Robin E Bachelder; Courtney Brown; Masabumi Shibuya; Peter Oettgen; Arthur M Mercurio
Journal:  Curr Biol       Date:  2003-09-30       Impact factor: 10.834

View more
  103 in total

1.  Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1.

Authors:  Gregory P Botta; Mauricio J Reginato; Maximilian Reichert; Anil K Rustgi; Peter I Lelkes
Journal:  Mol Cancer Res       Date:  2011-12-08       Impact factor: 5.852

Review 2.  Targeting protein kinases with selective and semipromiscuous covalent inhibitors.

Authors:  Rand M Miller; Jack Taunton
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

3.  A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration.

Authors:  Gromoslaw A Smolen; Jianmin Zhang; Matthew J Zubrowski; Elena J Edelman; Biao Luo; Min Yu; Lydia W Ng; Cally M Scherber; Benjamin J Schott; Sridhar Ramaswamy; Daniel Irimia; David E Root; Daniel A Haber
Journal:  Genes Dev       Date:  2010-11-09       Impact factor: 11.361

4.  The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells.

Authors:  K Belguise; S Milord; F Galtier; G Moquet-Torcy; M Piechaczyk; D Chalbos
Journal:  Oncogene       Date:  2012-01-30       Impact factor: 9.867

5.  Gossypin inhibits gastric cancer growth by direct targeting of AURKA and RSK2.

Authors:  Li Wang; Xiangyu Wang; Hanyong Chen; Xueyin Zu; Fayang Ma; Kangdong Liu; Ann M Bode; Zigang Dong; Dong Joon Kim
Journal:  Phytother Res       Date:  2018-12-10       Impact factor: 5.878

Review 6.  Covalent Inhibition in Drug Discovery.

Authors:  Avick Kumar Ghosh; Indranil Samanta; Anushree Mondal; Wenshe Ray Liu
Journal:  ChemMedChem       Date:  2019-03-26       Impact factor: 3.466

Review 7.  RSK isoforms in cancer cell invasion and metastasis.

Authors:  Florian J Sulzmaier; Joe W Ramos
Journal:  Cancer Res       Date:  2013-10-04       Impact factor: 12.701

8.  Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.

Authors:  Katarzyna A Ludwik; J Preston Campbell; Mingzong Li; Yu Li; Zachary M Sandusky; Lejla Pasic; Miranda E Sowder; David R Brenin; Jennifer A Pietenpol; George A O'Doherty; Deborah A Lannigan
Journal:  Mol Cancer Ther       Date:  2016-08-15       Impact factor: 6.261

9.  Yersinia virulence factor YopM induces sustained RSK activation by interfering with dephosphorylation.

Authors:  Moritz Hentschke; Laura Berneking; Cristina Belmar Campos; Friedrich Buck; Klaus Ruckdeschel; Martin Aepfelbacher
Journal:  PLoS One       Date:  2010-10-05       Impact factor: 3.240

Review 10.  Glycogen synthase kinase 3 beta: can it be a target for oral cancer.

Authors:  Rajakishore Mishra
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.